# Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

> **NCT04832399** · — · COMPLETED · sponsor: **Biogen** · enrollment: 60 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT04832399
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-12
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-10-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04832399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04832399, "Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04832399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*